Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

RenovoRx Inc

RNXT ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Micro Cap Analyst: BUY

Last Close

$1.40

▲ +11.11%

Market Cap $63.18M · Vol 124.26K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$63.18M

Micro Cap

Div Yield

N/A

EPS Growth

+17.19%

YoY

RSI (14)

79.04

Momentum

Beta

1.07

vs Market

52W High

$1.45

3.45% below

52W Low

$0.70

99.80% above

Volume

124.26K

Avg 39.27K

P/B

5.67

Price-to-book

ROE

N/A

Return on equity

Free Float

89.84%

Public shares

Shariah Compliance8 STANDARDS

✗ RenovoRx Inc (RNXT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RNXT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+25.00%

+64.71%

+63.74%

+50.01%

YTD

+66.65%

+12.90%

-21.79%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$1.12M
Net Income	$-11,168,000.00
Revenue Growth (YoY)	+115.40%
Gross Margin	70.88%
Operating Margin	-1,113.98%
Net Profit Margin	-994.48%
ROE	N/A
ROA · ROIC	-137.77% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	26.43
P/B	5.67
P/FCF	N/A
EPS Growth	+17.19%
Outstanding Shares	45.13M

Technical Indicators

50-Day SMA	$0.95
200-Day SMA	$0.94
RSI (14)	79.04
Beta	1.07
52-Week High	$1.45
52-Week Low	$0.70

Volume Today	124.26K
Avg Daily Volume (30D)	39.27K
Relative Volume	3.16x
Volatility (10D)	87.82
Volatility (30D)	75.96
Free Float	89.84%

Analyst Consensus

BUY

Current Price $1.40

Mean Target $7.00

52W Low$0.70 52W High$1.45

Current

Target

$0.70 $1.45

Current Analyst target

+400.00% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG005XWWZL5

ISINUS75989R1077

CountryUnited States of America

Sub-IndustryDrug Delivery Systems

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

SEDANA.ST Sedana Medical AB (publ) +2.48% ABT Abbott Laboratories -0.02% SYK Stryker Corp -0.55% MDT Medtronic PLC +0.76% EL.PA Essilorluxottica SA -0.73%

Company Profile

RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.